Video
Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study
Author(s):
Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.
Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cell-free Genome Atlas Study study in an interview with OncLive during the 2018 ASCO Annual Meeting.
Initial data from this study suggest that cell-free DNA assays can be used with a high degree of specificity to detect signs of early stage lung cancer.
Moreover, the study included 3 types of prototype sequencing assays. These included paired cfDNA and white blood cell targeted sequencing for single nucleotide variants/indels, paired cfDNA and WBC whole genome sequencing for copy number variation, and cfDNA whole genome bisulfite sequencing for methylation.
